Back to Browse Journals » Clinical Epidemiology » Volume 2

Positive predictive value and impact of misdiagnosis of a heart failure diagnosis in administrative registers among patients admitted to a University Hospital cardiac care unit

Authors Shan Mard, Finn Erland Nielsen

Published 1 October 2010 Volume 2010:2 Pages 235—239


Review by Single-blind

Peer reviewer comments 2

Shan Mard, Finn Erland Nielsen
Department of Cardiology, Herlev University Hospital, Denmark

Objective: To evaluate the positive predictive value (PPV) of a diagnosis of heart failure (HF) in the Danish National Registry of Patients (NRP) among patients admitted to a University Hospital cardiac care unit, and to evaluate the impact of misdiagnosing HF.
Design: The NRP was used to identify patients with heart failure from July 1, 2005 to June 30, 2007. Heart failure was defined in accordance with European Society of Cardiology (ESC) guidelines. The recorded diagnoses from the NRP were compared with clinical data from the medical records.
Results: We identified 758 patients with a diagnosis of heart failure in the NRP. The PPV of a heart failure discharge diagnosis was 84.0% (95% confidence interval: 81.2–86.6). Patients with a discharge diagnosis of HF in the NRP without fulfilling the ESC criteria for HF had a better survival rate, a lower rate of rehospitalization, none were followed in the outpatient clinic, and they had a lower consumption of anticongestive medicine after discharge.
Conclusion: We found a relatively high PPV of the HF diagnosis in the NRP, and the NRP can therefore be a valuable tool for identification of patients with HF. However, using the NRP alone will not give a true picture of the cost and total burden of the disease.

Keywords: heart failure, diagnosis, positive predictive value, National Registry of Patients

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

A new recombinant factor VIII: from genetics to clinical use

Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H

Drug Design, Development and Therapy 2015, 9:3817-3819

Published Date: 23 July 2015

Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia

Riva S, Nobili A, Djade CD, Mancuso ME, Santagostino E, Pravettoni G

Clinical Interventions in Aging 2015, 10:1141-1146

Published Date: 9 July 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson, Sisse R Ostrowski

Drug Design, Development and Therapy 2010, 4:107-116

Published Date: 29 June 2010